Ayerra, LeyreAbellanas, Miguel AngelVidaurre, ClaraBasurco, LeyreTavira, AdrianaLuquin, EstherClavero, PedroMengual, ElisaCollantes, MariaPeñuelas, Ivande Martin-Esteban, Samuel RuizGrether, UweHillard, Cecilia J.Romero, JulianHervás-Stubbs, SandraAymerich, Maria S.2025-12-192025-12-192025-08Ayerra, L, Abellanas, M A, Vidaurre, C, Basurco, L, Tavira, A, Luquin, E, Clavero, P, Mengual, E, Collantes, M, Peñuelas, I, de Martin-Esteban, S R, Grether, U, Hillard, C J, Romero, J, Hervás-Stubbs, S & Aymerich, M S 2025, 'Activation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson's disease', Brain, Behavior, and Immunity, vol. 128, pp. 600-611. https://doi.org/10.1016/j.bbi.2025.04.0370889-1591unpaywall: 10.1016/j.bbi.2025.04.037https://hdl.handle.net/10641/6805Publisher Copyright: © 2025 The Author(s)127524331enghttp://creativecommons.org/licenses/by-nc-nd/4.0/CD4 T cellsCannabinoid receptor type 2Endocannabinoid systemMicrogliaNeuroprotectionParkinson's diseaseImmunologyEndocrine and Autonomic SystemsBehavioral NeuroscienceJournal ArticleYesyesActivation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson's diseaseLa activación de los receptores cannabinoides centrales de tipo 2, pero no en las células inmunitarias periféricas, es necesaria para la neuroprotección mediada por endocannabinoides en la enfermedad de Parkinsonjournal articleopen access10.1016/j.bbi.2025.04.037https://www.scopus.com/pages/publications/105004306558https://www.scopus.com/pages/publications/105004306558#tab=citedBy